-
The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms.
Adv Cancer Res. 2000;79:157-73
PMID: 10818680
-
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Blood. 1999 Sep 15;94(6):1848-54
PMID: 10477713
-
The pathologist's view point. Part I--indolent lymphomas.
Haematologica. 2000 Dec;85(12):1291-307
PMID: 11114137
-
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.
Blood. 2001 May 1;97(9):2777-83
PMID: 11313271
-
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.
Blood. 2002 Feb 1;99(3):1023-9
PMID: 11807008
-
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.
Br J Haematol. 2001 Dec;115(4):854-61
PMID: 11843819
-
Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia.
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3854-9
PMID: 11891278
-
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
Blood. 2002 Aug 15;100(4):1410-6
PMID: 12149225
-
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Blood. 2002 Dec 15;100(13):4609-14
PMID: 12393534
-
Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA.
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15345-50
PMID: 12424339
-
The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
Blood. 2003 Feb 15;101(4):1262-9
PMID: 12406914
-
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
N Engl J Med. 2003 May 1;348(18):1764-75
PMID: 12724482
-
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Blood. 2003 Jun 15;101(12):4944-51
PMID: 12595313
-
Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes.
Blood. 1967 Apr;29(4):Suppl:566-84
PMID: 6022294
-
Studies of leukocyte kinetics in chronic lymphocytic leukemia.
Blood. 1968 Mar;31(3):277-91
PMID: 5640626
-
Lymphocyte kinetics in chronic lymphocytic leukaemia (CLL) studied by ECIB.
Br J Haematol. 1969 Oct;17(4):408
PMID: 4899589
-
Kinetics of lymphocytes in chronic lymphocytic leukemia. I. Equilibrium between blood and a "readily accessible pool".
Blood. 1973 Mar;41(3):425-38
PMID: 4690140
-
Kinetics of lymphocytes in chronic lymphocytic leukemia: studies using continuous 3H-thymidine infusion in two patients.
Blood. 1973 Oct;42(4):623-36
PMID: 4778708
-
Cell kinetics in chronic lymphocytic leukaemia (CLL).
Clin Haematol. 1977 Feb;6(1):159-67
PMID: 334407
-
Studies in chronic lymphocytic leukaemia. The kinetics of 51Cr-labelled lymphocytes.
Scand J Haematol. 1978 Jan;20(1):37-51
PMID: 580123
-
Biochemical characteristics of chronic lymphocytic leukaemia. Glucocorticoid receptors, B and T lymphocyte surface markers, concanavalin A-induced agglutination and thymidine incorporation.
Scand J Haematol. 1978 Nov;21(5):379-89
PMID: 310576
-
Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia.
Blood. 1979 Apr;53(4):594-603
PMID: 106861
-
3H-thymidine uptake in chronic lymphocytic leukaemia cells.
Scand J Haematol. 1980 Feb;24(2):169-73
PMID: 7375818
-
Chronic lymphocytic leukemia: a proliferative or accumulative disorder?
Leuk Res. 1983;7(1):1-10
PMID: 6834882
-
Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance.
Br J Haematol. 1986 Mar;62(3):567-75
PMID: 3954968
-
Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia.
Cancer. 1987 Dec 1;60(11):2712-6
PMID: 3677006
-
Metabolism and action of purine nucleoside analogs.
Pharmacol Ther. 1991;49(3):239-68
PMID: 1675805
-
B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL.
Blood. 1991 Oct 15;78(8):1901-14
PMID: 1912574
-
Evolution of leukemic heterogeneity of human B-CLL lymphocytes between and within patients.
Curr Top Microbiol Immunol. 1992;182:303-11
PMID: 1490369
-
Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study.
Histopathology. 1994 May;24(5):445-51
PMID: 8088716
-
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
Blood. 1996 Jun 15;87(12):4990-7
PMID: 8652811
-
Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose: studies in vitro, in animals, and in humans.
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):708-13
PMID: 9435257
-
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.
J Clin Invest. 1998 Oct 15;102(8):1515-25
PMID: 9788964
-
B-cell chronic lymphocytic leukemia: a bird of a different feather.
J Clin Oncol. 1999 Jan;17(1):399-408
PMID: 10458259
-
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Blood. 1999 Sep 15;94(6):1840-7
PMID: 10477712
-
Genomic aberrations and survival in chronic lymphocytic leukemia.
N Engl J Med. 2000 Dec 28;343(26):1910-6
PMID: 11136261